KR20140025303A - 급성 외상성 응고장애 및 소생된 심박 정지의 예방 또는 치료에 사용되는 내피 무결성을 조절／보존할 수 있는 화합물 - Google Patents

급성 외상성 응고장애 및 소생된 심박 정지의 예방 또는 치료에 사용되는 내피 무결성을 조절／보존할 수 있는 화합물 Download PDF

Info

Publication number
KR20140025303A
KR20140025303A KR1020137010342A KR20137010342A KR20140025303A KR 20140025303 A KR20140025303 A KR 20140025303A KR 1020137010342 A KR1020137010342 A KR 1020137010342A KR 20137010342 A KR20137010342 A KR 20137010342A KR 20140025303 A KR20140025303 A KR 20140025303A
Authority
KR
South Korea
Prior art keywords
compound
prostacyclin
value
coagulation
cut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137010342A
Other languages
English (en)
Korean (ko)
Inventor
파르 요한슨
시세 리에 오스트로우스키
Original Assignee
릭스하스피탈렛
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 릭스하스피탈렛 filed Critical 릭스하스피탈렛
Publication of KR20140025303A publication Critical patent/KR20140025303A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020137010342A 2010-10-01 2011-09-30 급성 외상성 응고장애 및 소생된 심박 정지의 예방 또는 치료에 사용되는 내피 무결성을 조절／보존할 수 있는 화합물 Withdrawn KR20140025303A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
PCT/DK2011/050375 WO2012041334A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Publications (1)

Publication Number Publication Date
KR20140025303A true KR20140025303A (ko) 2014-03-04

Family

ID=44872128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010342A Withdrawn KR20140025303A (ko) 2010-10-01 2011-09-30 급성 외상성 응고장애 및 소생된 심박 정지의 예방 또는 치료에 사용되는 내피 무결성을 조절／보존할 수 있는 화합물

Country Status (9)

Country Link
US (1) US20130261177A1 (https=)
EP (1) EP2622354A1 (https=)
JP (1) JP2013543491A (https=)
KR (1) KR20140025303A (https=)
CN (2) CN103238070B (https=)
AU (1) AU2011307494B2 (https=)
BR (1) BR112013007849A2 (https=)
CA (1) CA2812846A1 (https=)
WO (1) WO2012041334A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2832992A1 (en) * 2011-04-19 2012-10-26 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
EP2834642A1 (en) * 2012-03-30 2015-02-11 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
WO2015073314A1 (en) 2013-11-13 2015-05-21 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog
CN107250375A (zh) 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016126849A1 (en) * 2015-02-03 2016-08-11 The Regents Of The University Of Colorado, A Body Corporate Use of viscoelastic analysis for predicting massive hemorrhage
EP3278112B1 (en) 2015-03-29 2021-09-22 Endothel Pharma ApS A composition comprising prostacyclin or analogues thereof for treatment of acute critically ill patients
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
EP3455366A4 (en) 2016-05-11 2020-02-26 Michael P. Chapman ANALYSIS OF VISCOELASTICITY IN PATIENTS WITH A DISEASE ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
US12440285B2 (en) * 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US12105099B2 (en) * 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
WO1993025220A1 (en) * 1992-06-05 1993-12-23 Reid Thomas J Iii Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
RU2011132125A (ru) * 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
EP2525806B1 (en) * 2010-01-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Angiopoietin-like-protein-4 (ANGPTL4) for the preservation of vascular endothelial-cell barrier integrity

Also Published As

Publication number Publication date
AU2011307494B2 (en) 2015-08-06
AU2011307494A1 (en) 2013-05-02
WO2012041334A1 (en) 2012-04-05
US20130261177A1 (en) 2013-10-03
JP2013543491A (ja) 2013-12-05
CN106038570A (zh) 2016-10-26
CA2812846A1 (en) 2012-04-05
CN103238070A (zh) 2013-08-07
BR112013007849A2 (pt) 2016-06-07
CN103238070B (zh) 2016-06-29
EP2622354A1 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
AU2011307494B2 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
JP4989292B2 (ja) 血小板機能の流動状態下での測定方法および装置
van Ryn et al. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation
US9592236B2 (en) Methods of treating hemoglobinopathies
JP2012514014A (ja) 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
EP2207537B1 (en) Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
JP2007298512A (ja) 血小板機能の流動状態下での測定方法
Tkachenko et al. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease
Bird et al. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice
Taguchi et al. Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
WO2018166813A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Weber et al. Time course of systemic and renal plasma prostanoid concentrations and renal function in ovine hyperdynamic sepsis
Hitaka et al. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation
CA2614952A1 (en) Method of treating human volume expansion mediated hypertension employing resibufogenin
CA2543087A1 (en) Use of peroxisome proliferator-activated receptor gamma (ppar.gamma.) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
US20230218594A1 (en) Therapeutic compounds, compositions, and methods of use thereof
Burkard et al. Endothelial barrier dysfunction, loss of microcirculatory flow and organ failure in sepsis: current clinical view of sepsis and links to basic research
Malmström et al. New oral anticoagulants: focus on currently approved oral factor Xa and thrombin inhibitors
TW201134484A (en) Therapeutic use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160913

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20170109

WITB Written withdrawal of application